Large Polyglutamine Repeats Cause Muscle Degeneration in SCA17 Mice

Cell Reports

Volumn 13, Issue 1, 2015, Pages 196-208

  Huang, Shanshan ^a,b   Yang, Su ^a   Guo, Jifeng ^a   Yan, Sen ^a,c   Gaertig, Marta A ^a   Li, Shihua ^a   Li, Xiao Jiang ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE DERIVATIVE; MYOD PROTEIN; POLYGLUTAMINE; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR; CCAAT BINDING FACTOR; MYOD1 MYOGENIC DIFFERENTIATION PROTEIN; NFYA PROTEIN, MOUSE; PEPTIDE; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLAR ATAXIA; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; MALE; MOUSE; MOUSE STRAIN; MUSCLE ATROPHY; MUSCLE SPECIFIC GENE; NONHUMAN; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; SYMPTOM; ANIMAL; BINDING SITE; CEREBELLUM; CORPUS STRIATUM; CROSS BREEDING; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; HIPPOCAMPUS; HUMAN; METABOLISM; MUSCLE CELL; NERVE CELL; PATHOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SPINOCEREBELLAR DEGENERATION; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT;

ANIMALS; BINDING SITES; CCAAT-BINDING FACTOR; CEREBELLUM; CORPUS STRIATUM; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCK-IN TECHNIQUES; HIPPOCAMPUS; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUSCLE CELLS; MUSCLE, SKELETAL; MYOD PROTEIN; NEURONS; PEPTIDES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; SPINOCEREBELLAR ATAXIAS; TATA-BOX BINDING PROTEIN; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84943364527     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.08.060     Document Type: Article

References (44)

1. Andrews J.L., Zhang X., McCarthy J.J., McDearmon E.L., Hornberger T.A., Russell B., Campbell K.S., Arbogast S., Reid M.B., Walker J.R., et al. CLOCK and BMAL1 regulate MyoD and are necessary for maintenance of skeletal muscle phenotype and function. Proc. Natl. Acad. Sci. USA 2010, 107:19090-19095.
2. Bauer P., Laccone F., Rolfs A., Wüllner U., Bösch S., Peters H., Liebscher S., Scheible M., Epplen J.T., Weber B.H., et al. Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington's disease-like phenotype. J. Med. Genet. 2004, 41:230-232.
3. Bruni A.C., Takahashi-Fujigasaki J., Maltecca F., Foncin J.F., Servadio A., Casari G., D'Adamo P., Maletta R., Curcio S.A., De Michele G., et al. Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA box-binding protein mutation. Arch. Neurol. 2004, 61:1314-1320.
4. Brüning J.C., Michael M.D., Winnay J.N., Hayashi T., Hörsch D., Accili D., Goodyear L.J., Kahn C.R. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 1998, 2:559-569.
5. Chang Y.C., Lin C.Y., Hsu C.M., Lin H.C., Chen Y.H., Lee-Chen G.J., Su M.T., Ro L.S., Chen C.M., Hsieh-Li H.M. Neuroprotective effects of granulocyte-colony stimulating factor in a novel transgenic mouse model of SCA17. J. Neurochem. 2011, 118:288-303.
6. Cleary J.D., Ranum L.P. Repeat-associated non-ATG (RAN) translation in neurological disease. Hum. Mol. Genet. 2013, 22:R45-R51.
7. Cortes C.J., Ling S.C., Guo L.T., Hung G., Tsunemi T., Ly L., Tokunaga S., Lopez E., Sopher B.L., Bennett C.F., et al. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron 2014, 82:295-307.
8. Deato M.D., Tjian R. Switching of the core transcription machinery during myogenesis. Genes Dev. 2007, 21:2137-2149.
9. Deato M.D., Marr M.T., Sottero T., Inouye C., Hu P., Tjian R. MyoD targets TAF3/TRF3 to activate myogenin transcription. Mol. Cell 2008, 32:96-105.
10. Dedkov E.I., Kostrominova T.Y., Borisov A.B., Carlson B.M. MyoD and myogenin protein expression in skeletal muscles of senile rats. Cell Tissue Res. 2003, 311:401-416.
11. Degens H. The role of systemic inflammation in age-related muscle weakness and wasting. Scand. J Med. Sci. Sports 2010, 20:28-38.
12. Di Marco S., Mazroui R., Dallaire P., Chittur S., Tenenbaum S.A., Radzioch D., Marette A., Gallouzi I.E. NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol. Cell. Biol. 2005, 25:6533-6545.
13. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
14. Friedman M.J., Shah A.G., Fang Z.H., Ward E.G., Warren S.T., Li S., Li X.J. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat. Neurosci. 2007, 10:1519-1528.
15. Friedman M.J., Wang C.E., Li X.J., Li S. Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity. J. Biol. Chem. 2008, 283:8283-8290.
16. Gutekunst C.A., Li S.H., Yi H., Ferrante R.J., Li X.J., Hersch S.M. The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J. Neurosci. 1998, 18:7674-7686.
17. Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.Y., Baldwin A.S. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000, 289:2363-2366.
18. Hawke T.J., Garry D.J. Myogenic satellite cells: physiology to molecular biology. J. Appl. Physiol. (1985) 2001, 91:534-551.
19. Heller H., Bengal E. TFIID (TBP) stabilizes the binding of MyoD to its DNA site at the promoter and MyoD facilitates the association of TFIIB with the preinitiation complex. Nucleic Acids Res. 1998, 26:2112-2119.
20. Holzenberger M., Lenzner C., Leneuve P., Zaoui R., Hamard G., Vaulont S., Bouc Y.L. Cre-mediated germline mosaicism: a method allowing rapid generation of several alleles of a target gene. Nucleic Acids Res. 2000, 28:E92.
21. Huang S., Ling J.J., Yang S., Li X.J., Li S. Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor. Brain 2011, 134:1943-1958.
22. Ishido M., Kami K., Masuhara M. In vivo expression patterns of MyoD, p21, and Rb proteins in myonuclei and satellite cells of denervated rat skeletal muscle. Am. J. Physiol. Cell Physiol. 2004, 287:C484-C493.
23. Kelp A., Koeppen A.H., Petrasch-Parwez E., Calaminus C., Bauer C., Portal E., Yu-Taeger L., Pichler B., Bauer P., Riess O., Nguyen H.P. A novel transgenic rat model for spinocerebellar ataxia type 17 recapitulates neuropathological changes and supplies in vivo imaging biomarkers. J. Neurosci. 2013, 33:9068-9081.
24. Koide R., Kobayashi S., Shimohata T., Ikeuchi T., Maruyama M., Saito M., Yamada M., Takahashi H., Tsuji S. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease?. Hum. Mol. Genet. 1999, 8:2047-2053.
25. Lakso M., Pichel J.G., Gorman J.R., Sauer B., Okamoto Y., Lee E., Alt F.W., Westphal H. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl. Acad. Sci. USA 1996, 93:5860-5865.
26. Legerlotz K., Smith H.K. Role of MyoD in denervated, disused, and exercised muscle. Muscle Nerve 2008, 38:1087-1100.
27. Lieberman A.P., Yu Z., Murray S., Peralta R., Low A., Guo S., Yu X.X., Cortes C.J., Bennett C.F., Monia B.P., et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 2014, 7:774-784.
28. Lim J., Crespo-Barreto J., Jafar-Nejad P., Bowman A.B., Richman R., Hill D.E., Orr H.T., Zoghbi H.Y. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008, 452:713-718.
29. Maltecca F., Filla A., Castaldo I., Coppola G., Fragassi N.A., Carella M., Bruni A., Cocozza S., Casari G., Servadio A., De Michele G. Intergenerational instability and marked anticipation in SCA-17. Neurology 2003, 61:1441-1443.
30. Mielcarek M., Toczek M., Smeets C.J., Franklin S.A., Bondulich M.K., Jolinon N., Muller T., Ahmed M., Dick J.R., Piotrowska I., et al. HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy. PLoS Genet. 2015, 11:e1005021.
31. Nakamura K., Jeong S.Y., Uchihara T., Anno M., Nagashima K., Nagashima T., Ikeda S., Tsuji S., Kanazawa I. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet. 2001, 10:1441-1448.
32. Orr H.T., Zoghbi H.Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 2007, 30:575-621.
33. Portal E., Riess O., Nguyen H.P. Automated home cage assessment shows behavioral changes in a transgenic mouse model of spinocerebellar ataxia type 17. Behav. Brain Res. 2013, 250:157-165.
34. Rolfs A., Koeppen A.H., Bauer I., Bauer P., Buhlmann S., Topka H., Schöls L., Riess O. Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann. Neurol. 2003, 54:367-375.
35. Rudnicki M.A., Braun T., Hinuma S., Jaenisch R. Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. Cell 1992, 71:383-390.
36. Squitieri F., Ciarmiello A., Di Donato S., Frati L. The search for cerebral biomarkers of Huntington's disease: a review of genetic models of age at onset prediction. Eur. J. Neurol. 2006, 13:408-415.
37. Tanaka Y., Yamaguchi A., Fujikawa T., Sakuma K., Morita I., Ishii K. Expression of mRNA for specific fibroblast growth factors associates with that of the myogenic markers MyoD and proliferating cell nuclear antigen in regenerating and overloaded rat plantaris muscle. Acta Physiol. (Oxf.) 2008, 194:149-159.
38. Tapscott S.J. The circuitry of a master switch: Myod and the regulation of skeletal muscle gene transcription. Development 2005, 132:2685-2695.
39. Tapscott S.J., Davis R.L., Thayer M.J., Cheng P.F., Weintraub H., Lassar A.B. MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science 1988, 242:405-411.
40. Toyoshima Y., Yamada M., Onodera O., Shimohata M., Inenaga C., Fujita N., Morita M., Tsuji S., Takahashi H. SCA17 homozygote showing Huntington's disease-like phenotype. Ann. Neurol. 2004, 55:281-286.
41. Vannini A., Cramer P. Conservation between the RNA polymerase I, II, and III transcription initiation machineries. Mol. Cell 2012, 45:439-446.
42. van Roon-Mom W.M., Reid S.J., Faull R.L., Snell R.G. TATA-binding protein in neurodegenerative disease. Neuroscience 2005, 133:863-872.
43. Vargas A.P., Carod-Artal F.J., Bomfim D., Vázquez-Cabrera C., Dantas-Barbosa C. Unusual early-onset Huntingtons disease. J. Child Neurol. 2003, 18:429-432.
44. Yang S., Huang S., Gaertig M.A., Li X.J., Li S. Age-dependent decrease in chaperone activity impairs MANF expression, leading to Purkinje cell degeneration in inducible SCA17 mice. Neuron 2014, 81:349-365.